Trial reportInfluenza and other respiratory viruses2011
An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years.
Trial report in Influenza and other respiratory viruses, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Vaccines for preventing influenza in healthy children.The Cochrane database of systematic reviews · 2018Pooled it
- Vaccines for preventing influenza in healthy children.The Cochrane database of systematic reviews · 2012Pooled it
- Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses.Human vaccines & immunotherapeutics · 2012Pooled it
- Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma.The Journal of allergy and clinical immunology · 2020Trial
- The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies.Influenza and other respiratory viruses · 2018Trial
- Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study.BMJ (Clinical research ed.) · 2015Trial
- The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Trial
- The Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention.The Medical journal of Australia · 2026Article
- MiRNA Targeted NP Genome of Live Attenuated Influenza Vaccines Provide Cross-Protection against a Lethal Influenza Virus Infection.Vaccines · 2020Article
- Article
- Influenza vaccines: Evaluation of the safety profile.Human vaccines & immunotherapeutics · 2018Review
- Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine.PloS one · 2017Article
- Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Live attenuated influenza vaccine (Fluenz™): a guide to its use in the prevention of seasonal influenza in children in the EU.Paediatric drugs · 2012Article
- Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.Vaccine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrivalent, Ann Arbor strain, live attenuated influenza vaccine (LAIV) is approved in several countries for use in eligible children aged ≥2 years.
objectiveTo describe the safety of Ann Arbor strain LAIV in children aged 2-17 years.
methodsAn integrated analysis of randomized, controlled trials of LAIV.
resultsA total of 4245 and 10,693 children received ≥1 dose of LAIV in year 1 of 6 trivalent inactivated influenza vaccine (TIV)-controlled and 14 placebo-controlled studies, respectively; 3212 children were revaccinated in year 2 of 4 placebo-controlled studies. Compared with placebo for days 0-10 post-vaccination, LAIV recipients exhibited increased runny/stuffy nose (+7%), headache (+7%), and tiredness/decreased activity (+2%) after dose 1; and a higher rate of decreased appetite (+4%) after year 2 revaccination. Compared with TIV, only runny/stuffy nose was increased (dose 1, +12%; dose 2, +4%). Compared with initial vaccination, LAIV reactogenicity was lower after dose 2 in year 1 and revaccination in year 2. Unsolicited adverse events (AEs) increased with LAIV in some comparisons were headache, nasal congestion/rhinorrhea, rhinitis, and pyrexia; ear pain and lower respiratory illness were decreased. There was no evidence of an increase in any potential vaccine-related serious AE in LAIV recipients. Among children aged 2-17 years and specifically aged 24-35 months, there was no evidence that lower respiratory illness or wheezing illness occurred at a higher rate in LAIV recipients.
conclusionThis analysis supports the safety of Ann Arbor strain LAIV in children aged 2-17 years and provides a consensus assessment of events expected after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.